IRIS
BARCHIESI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.893
EU - Europa 4.714
AS - Asia 4.467
SA - Sud America 1.223
AF - Africa 235
Continente sconosciuto - Info sul continente non disponibili 234
OC - Oceania 4
Totale 20.770
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.714
SG - Singapore 1.379
VN - Vietnam 996
BR - Brasile 925
RU - Federazione Russa 791
UA - Ucraina 785
IT - Italia 684
CN - Cina 578
DE - Germania 458
IE - Irlanda 458
TR - Turchia 456
SE - Svezia 379
HK - Hong Kong 347
FR - Francia 288
DK - Danimarca 284
FI - Finlandia 208
GB - Regno Unito 196
KR - Corea 158
AR - Argentina 109
BD - Bangladesh 105
IN - India 95
CI - Costa d'Avorio 92
CA - Canada 73
MX - Messico 62
EC - Ecuador 50
ZA - Sudafrica 48
ID - Indonesia 47
NL - Olanda 46
IQ - Iraq 41
CO - Colombia 38
JP - Giappone 29
PL - Polonia 28
PK - Pakistan 27
PY - Paraguay 26
CL - Cile 25
IR - Iran 24
MA - Marocco 23
PH - Filippine 22
VE - Venezuela 21
AT - Austria 20
ES - Italia 20
UZ - Uzbekistan 20
MY - Malesia 15
SA - Arabia Saudita 15
AZ - Azerbaigian 13
BE - Belgio 13
EG - Egitto 13
TN - Tunisia 13
PE - Perù 12
KZ - Kazakistan 11
UY - Uruguay 11
KE - Kenya 10
BA - Bosnia-Erzegovina 9
JO - Giordania 9
TH - Thailandia 9
DZ - Algeria 8
CR - Costa Rica 7
IL - Israele 7
JM - Giamaica 7
KW - Kuwait 7
NP - Nepal 7
CZ - Repubblica Ceca 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
EU - Europa 6
HN - Honduras 6
LB - Libano 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
LT - Lituania 5
MD - Moldavia 5
PS - Palestinian Territory 5
AO - Angola 4
AU - Australia 4
BH - Bahrain 4
BO - Bolivia 4
BY - Bielorussia 4
KG - Kirghizistan 4
NG - Nigeria 4
PA - Panama 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AM - Armenia 3
HR - Croazia 3
LK - Sri Lanka 3
OM - Oman 3
PT - Portogallo 3
SN - Senegal 3
SV - El Salvador 3
BG - Bulgaria 2
CH - Svizzera 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
HU - Ungheria 2
MU - Mauritius 2
NO - Norvegia 2
PR - Porto Rico 2
QA - Qatar 2
Totale 20.517
Salva come PNG Salva come JPEG
Città #
Ashburn 1.552
Singapore 844
Jacksonville 792
Fairfield 737
Dallas 591
Chandler 528
Dublin 452
Boardman 420
Hong Kong 326
Ho Chi Minh City 321
Wilmington 313
Woodbridge 304
Council Bluffs 294
San Jose 291
Seattle 257
Houston 250
New York 250
Des Moines 243
Cambridge 239
Hanoi 220
The Dalles 200
Ann Arbor 180
Lawrence 172
Princeton 172
San Mateo 171
Lauterbourg 150
Moscow 140
Los Angeles 131
Beijing 122
Turin 106
San Diego 97
Abidjan 92
Milan 92
Hefei 88
Munich 82
São Paulo 77
Da Nang 63
Buffalo 52
Chicago 51
Haiphong 46
Centro 43
London 40
Helsinki 38
Santa Clara 38
Rio de Janeiro 32
Redmond 31
Nuremberg 29
Shanghai 28
Miano 27
Ancona 26
Brooklyn 26
Montreal 23
Tokyo 23
Turku 23
Frankfurt am Main 22
Orem 22
Biên Hòa 21
Columbus 21
Johannesburg 21
Warsaw 20
Boston 19
Mexico City 19
Tashkent 19
Chennai 18
Guayaquil 18
Norwalk 18
Washington 18
Dhaka 17
Guangzhou 17
Pune 17
Baghdad 16
Belo Horizonte 16
Ninh Bình 16
Ottawa 16
Brasília 15
Nha Trang 15
Quito 15
Amsterdam 14
Curitiba 14
Marche 14
Porto Alegre 14
Salt Lake City 14
Wuhan 14
Atlanta 13
Hải Dương 13
Kilburn 13
Stockholm 13
Ankara 12
Brussels 12
Cape Town 12
Phoenix 12
Rome 12
Asunción 11
Baku 11
Bologna 11
Mumbai 11
Naples 11
Poplar 11
Campinas 10
Caracas 10
Totale 12.633
Salva come PNG Salva come JPEG
Nome #
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. 214
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients 203
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway 202
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study 199
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. 191
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 191
Aspergillus spp invasive external otitis: favourable outcome with a medical approach 190
Candida guilliermondii fungemia in patients with hematologic malignancies. 186
Antimicrobial activity of polycationic peptides 184
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases 183
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study 177
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature 174
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards 172
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection 166
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature 164
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 163
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. 163
Epidemiology and microbiology of surgical wound infections. 159
Candidemia in the elderly: What does it change? 157
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy 154
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. 154
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 152
Characterisation of candidemia in patients with recent surgery: A 7-year experience 152
Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. 151
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey 150
Genotypic and phenotypic characteristics of Candida parapsilosis bloodstream isolates: Health Care Associated Infections in a teaching Hospital in Italy 148
In-vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 148
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes 148
Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. 147
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry 143
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU 143
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex 142
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals 141
Trichosporon beigelii fungaemia in an AIDS patient. 139
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. 139
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy 138
Antifungal Combinations against Candida Species: From Bench to Bedside 137
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp. 137
Antifungal combinations in dermatophytes 137
Candidemia in Internal Medicine: Facing the New Challenge 135
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. 133
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 133
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. 133
Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from the oral cavities of aids patients. 132
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases 132
Anticryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. 132
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). 131
Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. 127
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. 126
Antiretroviral therapy management and rationalisation of available resources 126
A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication 126
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. 125
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 125
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 124
EUCAST technical note on posaconazole. 123
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. 123
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. 122
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. 122
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors 121
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes 120
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 119
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. 119
Voriconazole and multidrug resistance in Candida albicans. 118
Reply to Ma et al.: Osteomyelitis caused by aspergillus species 118
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 116
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 116
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. 116
In-vitro activity of rifabutin and albendazolo singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 115
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. 114
EUCAST Technical Note on voriconazole. 114
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. 114
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. 113
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 113
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches 113
The Clinical Characteristics of Bloodstream Infections Due to Candida spp. in Patients Hospitalized in Intensive Care Units during the SARS-CoV-2 Pandemic: The Results of a Multicenter Study 112
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata 112
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. 112
Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 112
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates 112
Prevalence and predictors of malignancies in HIV patients: results of a retrospective multicentric Italian cohort. 112
Clinical and molecular characteristics of KPC-producing Klebsiella pneumoniae bloodstream infections: Results of a multicentre study 112
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata 111
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. 111
Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates 111
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report. 111
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot 110
Tolerance to amphotericin B in clinical isolates of Candida tropicalis. 110
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. 109
Caspofungin in combination with amphotericin B against Candida parapsilosis. 109
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 109
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. 108
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes. 108
EUCAST technical note on Amphotericin B 108
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 108
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. 107
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. 106
Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years 105
In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. 105
Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. 105
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. 105
Totale 13.467
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.330
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.330
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.373 0 432 13 41 20 62 112 70 76 134 155 258
2022/20232.039 212 168 147 109 133 353 11 94 558 11 173 70
2023/20241.266 211 25 67 239 246 273 25 18 10 13 10 129
2024/20252.312 210 201 164 28 61 58 166 108 607 156 232 321
2025/20268.056 401 576 732 1.111 657 397 1.358 752 702 687 302 381
2026/2027569 387 182 0 0 0 0 0 0 0 0 0 0
Totale 20.770